VABIOTECH

Name

VABIOTECH

Legal name

Công ty TNHH MTV Vắc xin và Sinh phẩm số 1

Website

https://vabiotech.com.vn

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Travel & Tropical Disease Vaccines (HLAIAEAE)

akta.pro secondary industries

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)

Keywords

• Vaccine manufacturing
• Biological products
• Hepatitis vaccines
• Japanese encephalitis vaccine
• Vaccination services

Headquarters

HQ city

Hanoi

HQ country

Vietnam

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Vaccine Manufacturing and Sales: Domestic production and sale of four vaccine types (Hepatitis A, Hepatitis B, Japanese Encephalitis, Oral Cholera) to government procurement, healthcare facilities, and the Expanded Immunization Programme. Revenue is generated through bulk supply contracts with the Ministry of Health and public health channels. In 2025, produced 6.54 million domestic doses and consumed over 10 million total doses.
2. Imported Vaccine Distribution: Import and distribution of vaccines manufactured by international partners, including combination vaccines (DPT-VGB-Hib), MMR, rabies, pneumococcal, meningococcal, varicella, and blood products (albumin, IVIg). Revenue generated through commercial distribution channels.
3. Vaccination Services: Direct vaccination service provision through VABIOTECH Care clinics offering routine immunizations, travel vaccinations, and seasonal flu shots. Revenue from service fees charged to individuals and organizations at two clinic facilities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

VABIOTECH is a state-owned vaccine and biological products manufacturer under Vietnam's Ministry of Health, domestically producing four vaccine types (Hepatitis A – HAVAX®, Recombinant Hepatitis B – Gene-HBvax, Japanese Encephalitis – JEVAX®, and Oral Cholera – mORCVAX) using cell culture, recombinant DNA, and plasma fractionation technologies. The company also imports and distributes vaccines and blood-derived products from international manufacturers, and operates two VABIOTECH Care vaccination clinics in Hanoi offering routine, travel, and seasonal immunizations directly to consumers.

Product overview

VABIOTECH operates as a state-owned vaccine and biological products manufacturer under Vietnam's Ministry of Health, producing four domestically manufactured vaccines (HAVAX®, Gene-HBvax, JEVAX®, mORCVAX) while also importing and distributing vaccines from international manufacturers. The company provides vaccination services through its VABIOTECH Care centers and is developing several new vaccines currently under registration, including Varicella, HPV, Hand Foot and Mouth Disease, Rabies (RABIVAX-S), and Pneumococcal vaccines. The product portfolio spans hepatitis vaccines, Japanese encephalitis vaccine, cholera vaccine, and upcoming vaccines targeting chickenpox, cervical cancer, hand-foot-mouth disease, rabies, and pneumococcal infections.

Differentiator

Problem solved

Functional benefit

Brands

• VABIOTECH Care: Vaccination services brand offering routine immunizations, travel vaccinations, and seasonal vaccinations. Operates vaccination centers at Mac Thai Tong Facility and Thang Long International Village Facility.

Products and services

• HAVAX® Hepatitis A vaccine manufactured by VABIOTECH for protection against Hepatitis A virus infection, supplied to Vietnam's Expanded Immunization Programme.
• Gene-HBvax Recombinant Hepatitis B vaccine produced using recombinant DNA technology for Hepatitis B virus protection, supplied to the national immunization program.
• JEVAX® Japanese Encephalitis vaccine manufactured domestically for protection against Japanese Encephalitis virus transmitted by mosquitoes, supplied to the EPI.
• mORCVAX Oral cholera vaccine produced domestically for protection against cholera infection.
• VABIOTECH Care Vaccination Services Comprehensive vaccination services including routine immunizations for children and adults, travel vaccinations, and seasonal flu shots, offered directly to individual consumers at two facilities in Hanoi under the VABIOTECH Care brand.
• Imported vaccine distribution (DPT-VGB-Hib, MMR, rabies, pneumococcal, meningococcal VA-MENGOC-BC, varicella) Import and distribution of vaccines manufactured by international partners, including the DPT-VGB-Hib 5-in-1 combination vaccine, MMR, rabies, pneumococcal, meningococcal (VA-MENGOC-BC), and varicella vaccines, supplied through commercial channels and the EPI.
• Blood-derived biological products (Albumin, IVIg) Plasma fractionation-derived biological products including Albumin and intravenous immunoglobulin (IVIg) for clinical use in healthcare facilities.

Quantifiable outcome

• Supplied over 3.6 million doses of domestically manufactured vaccines to the Expanded Immunization Programme in 2025.
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Australian Universities (via Ministry of Health Delegation)minorStrategic or Co-development Partner · 1 January 2025A Vietnamese Ministry of Health delegation, including VABIOTECH, conducted meetings with Australian universities in June 2026 to strengthen cooperation in medical training and advanced technology applications in healthcare.
• World Health Organization (WHO)coreStrategic or Co-development PartnerVABIOTECH collaborates with WHO on vaccine quality standards, regulatory guidance, and international vaccine technology frameworks. WHO serves as a key reference body for VABIOTECH's manufacturing quality and prequalification efforts.
• UNICEFcoreStrategic or Co-development PartnerUNICEF is a key global procurement partner for vaccines supplied by VABIOTECH, facilitating access to international vaccine markets and supporting supply chain logistics for the national immunization program.
• Gavi, the Vaccine AlliancecoreStrategic or Co-development PartnerGavi supports Vietnam's immunization program and partners with VABIOTECH on vaccine introduction, supply security, and introduction of new vaccines into the national program.
• International Vaccine Institute (IVI)minorStrategic or Co-development PartnerVABIOTECH collaborates with IVI on vaccine research, development, and technology transfer for vaccine candidates of international public health importance.
• Korea International Cooperation Agency (KOICA)minorStrategic or Co-development PartnerKOICA partners with VABIOTECH through Korean government development cooperation programs supporting healthcare infrastructure and vaccine technology advancement in Vietnam.
• Japan International Cooperation Agency (JICA)minorStrategic or Co-development PartnerJICA supports capacity building and technology cooperation with VABIOTECH, including training and technology transfer in vaccine manufacturing quality standards.
• Serum Institute of IndiacoreTechnology or IntegrationSerum Institute of India is a key international supplier whose vaccines are imported and distributed by VABIOTECH in Vietnam, including DPT combination and other pediatric vaccines.
• Bill & Melinda Gates FoundationminorStrategic or Co-development PartnerThe Gates Foundation supports global health initiatives that may involve VABIOTECH's vaccine programs and technology advancement efforts through funding and technical assistance.
• National Institute of Hygiene and Epidemiology (NIHE) / Viện Vệ sinh Dịch tễ Trung ươngcoreStrategic or Co-development PartnerVABIOTECH originated as a unit under NIHE. The company maintains a close operational and research relationship with NIHE as a key government research institution in epidemiology and vaccine development.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bharat Biotech: Indian vaccine manufacturer with a comparable emerging-market focus, broad vaccine portfolio (hepatitis, JE, cholera, rotavirus), and similar government-channel positioning. Operates at a larger scale but mirrors VABIOTECH's tropical disease vaccine focus.
• Finlay Vaccine Institute (Cuba): State-owned Cuban vaccine manufacturer — closely comparable to VABIOTECH in ownership structure (government), emerging-market focus, and WHO/UNICEF partnership profile. VABIOTECH distributes Finlay's VA-MENGOC-BC meningococcal vaccine in Vietnam.
• Biological E: Indian vaccine and biologics manufacturer listed among VABIOTECH's international partners, with comparable product breadth in routine pediatric and combination vaccines. Direct channel and product overlap.
• SK Bioscience: South Korean vaccine developer and manufacturer partnered with VABIOTECH. Comparable in technology platforms (cell culture, recombinant) and target on government immunization programs and emerging disease vaccines.
• Serum Institute of India: World's largest vaccine manufacturer by doses; directly comparable as a high-volume emerging-market producer supplying WHO/Gavi/UNICEF channels. VABIOTECH is also a distribution partner and importer of Serum Institute products in Vietnam.

Broad incumbents

• GSK Vaccines: Global vaccine incumbent covering most of VABIOTECH's therapeutic areas (hepatitis A/B, HPV, pneumococcal). Represents the global standard that VABIOTECH must compete with or partner around for WHO prequalification.
• Sanofi Pasteur: Global vaccine major and broad incumbent in the same product categories (hepatitis, JE, cholera, rabies). Represents both a potential technology partner and competitive threat as it expands emerging-market presence.

Emerging players

• Panacea Biotec: Indian vaccine manufacturer with overlapping focus on pediatric combination vaccines (DPT, polio, hepatitis) supplied through UNICEF and government channels. Comparable emerging-market vaccine manufacturer profile.
• Hualan Biological Engineering: Chinese vaccine and plasma-derived biologics manufacturer with comparable focus on hepatitis, flu, and plasma fractionation. Similar portfolio breadth to VABIOTECH and regional emerging-market supplier profile.

Regional players

• China National Biotec Group (CNBG / Sinopharm): China's largest state-owned vaccine and biologics manufacturer — closely comparable to VABIOTECH in ownership structure, regulatory positioning, and emerging-market export focus, though at substantially greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@vabiotechvietnam930
• Facebookfacebook.com/VabiotechVietNam
• Xx.com/vabiotech
• LinkedInlinkedin.com/company/vabiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VABIOTECH